Research
Eli Lilly: The Beat Was Enormous — and the Question It Leaves Is About Size, Not Execution
Revenue $24,397M, +8.03% vs estimate and +38.61% YoY · non-GAAP EPS $7.48 vs $5.68 (+31.69%) · guidance raised to $91–92B of revenue and $35–36 of EPS — and the close was +6.57% to $1,373